Antibiotic resistance (AR) poses a significant threat to global health, jeopardizing the efficacy of treatments for bacterial infections.  The rise of multi-drug resistant (MDR) pathogens necessitates urgent research into novel therapeutic strategies, yet experimental investigations face substantial challenges.  Accurately simulating the complex in vivo environment, including host immune responses and the microbiome, remains a significant hurdle in pre-clinical studies.  In vitro models often fail to recapitulate the heterogeneity of bacterial populations and the intricate interactions within biofilms, leading to inaccurate estimations of antibiotic efficacy and resistance development.  Furthermore, translating findings from animal models to humans is complicated by interspecies differences in pharmacokinetics and pharmacodynamics.  Standardization of experimental methodologies across different labs is also crucial but challenging to achieve, hindering comparability and reproducibility of results.  Addressing these experimental challenges requires a multidisciplinary approach encompassing advanced in vitro models (e.g., organ-on-a-chip), sophisticated in vivo models reflecting human physiology, and the development of robust and standardized protocols for evaluating antibiotic efficacy and resistance mechanisms.  Overcoming these hurdles is essential for accelerating the development and deployment of effective countermeasures against AR.